NCM Boston | Oxford Nanopore Technologies
NCM Boston
NCM Boston
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Oxford Nanopore Technologies
Bradley Hall
)
- Job title
- Institution
- Asuragen, USA
- Biography
Bradley Hall received his PhD in molecular biology from The University of Texas in 2008. There, he developed the Aptamer Stream within the Freshman Research Initiative, the largest undergraduate research program in the US. He transitioned to Altermune Technologies in 2010, founded by Nobel laureate Kary Mullis, where he focused on immune-redirecting therapies. In 2016, Brad joined Asuragen where he is currently Director of R&D with work focused on advancing nanopore sequencing in clinical laboratories with accessible testing kits.
- Recent publications
Hall, B. et al. A dual-mode targeted nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis. medRxiv 2024.02.22.24303180; (2024).
DOI: 10.1101/2024.02.22.24303180Hall B. et al. Multisite Verification of a Targeted CFTR Polymerase Chain Reaction/Capillary Electrophoresis Assay That Evaluates Pathogenic Variants Across Diverse Ethnic and Ancestral Groups. Arch Pathol Lab Med. (2024).
DOI: 10.5858/arpa.2023-0230-OA.